Janar Sathananthan, Ole De Backer, and Michael Reardon dive into the newest findings on TAVR from the late-breaking ACURATE IDE trial.

Though X (formerly Twitter) was once a place many cardiologists found community and opportunity, many are jumping ship.

An increased risk of cardiovascular disease may be present as early as 30 years before a type 2 diabetes diagnosis is made, ...

The SMART trial raised questions about balloon-expandable valves in small aortic annuli; these new data offer some answers.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

Written to offer advice where formal guidelines fall short, the document urges a balance between bleeding and ischemic risk.

The study was stopped early to allow all patients with advanced PAH the option for treatment with the activin signaling ...

A multistate model that enables real-time risk recalculations may help improve risk stratification for prediction of ...

Investigators saw more deaths in patients with severe TR after repeat mitral valve procedures; what to do about it is unclear ...